Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

506 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial.
Ross AE, Zhang J, Huang HC, Yamashita R, Keim-Malpass J, Simko JP, DeVries S, Morgan TM, Souhami L, Dobelbower MC, McGinnis LS, Jones CU, Dess RT, Zeitzer KL, Choi K, Hartford AC, Michalski JM, Raben A, Gomella LG, Sartor AO, Rosenthal SA, Sandler HM, Spratt DE, Pugh SL, Mohamad O, Esteva A, Chen E, Schaeffer EM, Tran PT, Feng FY. Ross AE, et al. Among authors: feng fy. Eur Urol Oncol. 2024 Jan 31:S2588-9311(24)00029-4. doi: 10.1016/j.euo.2024.01.004. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38302323
Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation.
Sabolch A, Feng FY, Daignault-Newton S, Halverson S, Blas K, Phelps L, Olson KB, Sandler HM, Hamstra DA. Sabolch A, et al. Among authors: feng fy. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e351-60. doi: 10.1016/j.ijrobp.2011.01.063. Epub 2011 Apr 13. Int J Radiat Oncol Biol Phys. 2011. PMID: 21493015
The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
Shilkrut M, Merrick GS, McLaughlin PW, Stenmark MH, Abu-Isa E, Vance SM, Sandler HM, Feng FY, Hamstra DA. Shilkrut M, et al. Among authors: feng fy. Cancer. 2013 Feb 1;119(3):681-90. doi: 10.1002/cncr.27784. Epub 2012 Aug 14. Cancer. 2013. PMID: 22893254 Free article.
A prostate-specific antigen doubling time of <6 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy.
Jackson WC, Johnson SB, Li D, Foster C, Foster B, Song Y, Schipper M, Shilkrut M, Sandler HM, Morgan TM, Palapattu GS, Hamstra DA, Feng FY. Jackson WC, et al. Among authors: feng fy. Radiat Oncol. 2013 Jul 8;8:170. doi: 10.1186/1748-717X-8-170. Radiat Oncol. 2013. PMID: 23835115 Free PMC article.
506 results